Rebamipide promotes lacrimal duct epithelial cell survival via protecting barrier function
Nasolacrimal duct obstruction (NLDO) is thought to be due to inflammation and fibrosis of lacrimal duct epithelial cells (LDECs). Here we investigated the effect of rebamipide, a drug that is used for the protection of the mucosa and the treatment of gastritis and gastroduodenal ulcers, on LDECs, bo...
Gespeichert in:
Veröffentlicht in: | Scientific reports 2020-02, Vol.10 (1), p.1641-1641, Article 1641 |
---|---|
Hauptverfasser: | , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Nasolacrimal duct obstruction (NLDO) is thought to be due to inflammation and fibrosis of lacrimal duct epithelial cells (LDECs). Here we investigated the effect of rebamipide, a drug that is used for the protection of the mucosa and the treatment of gastritis and gastroduodenal ulcers, on LDECs, both
in vitro
and
in vivo
. In this study, LDECs were cultured from rabbit lacrimal duct tissues, and the barrier function of LEDCs was examined
in vitro
via transepithelial electrical resistance (TER) measurement, with or without interleukin (IL)-6 and/or rebamipide. For the
in vivo
examination, benzalkonium chloride (BAC) was injected into the rabbit lacrimal ducts, followed by the application of rebamipide or a placebo vehicle alone. The results of the
in vitro
examination revealed a significant decrease in TER in the group treated with IL-6 alone compared with the placebo-vehicle group (
p
|
---|---|
ISSN: | 2045-2322 2045-2322 |
DOI: | 10.1038/s41598-020-58314-x |